SCHEMBL3089943

SCHEMBL3089943

Cc1oc(-c2cccnc2)cc1C(O)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.45
TDO2 P48775 2/20 0.45
PDE4A P27815 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CDK2 P24941 2/20 0.40
GSK3B P49841 2/20 0.40
BACE1 P56817 1/20 0.38
KCNH2 Q12809 1/20 0.38
RAB9A P51151 1/20 0.38
KDR P35968 1/20 0.37
BRD4 O60885 1/20 0.37
CYP2A6 P11509 2/20 0.36
CYP2E1 P05181 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
MMP13 P45452 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3106764 0.86 PDE4A (0.41) IDO1TDO2PDE4AALDH1A1CDK2
SCHEMBL3109648 0.85 BRD4 (0.39) IDO1TDO2PDE4ARAB9ABRD4
SCHEMBL3113043 0.85 ALDH1A1 (0.39) IDO1TDO2ALDH1A1RAB9ABRD4
SCHEMBL3090921 0.84 BRD4 (0.37) IDO1TDO2GSK3BKCNH2BRD4
SCHEMBL3095541 0.83 ALDH1A1 (0.40) IDO1TDO2ALDH1A1RAB9ABRD4
SCHEMBL3095257 0.83 BRD4 (0.38) IDO1TDO2BRD4CYP1A1CYP1A2
SCHEMBL3111415 0.81 ALDH1A1 (0.40) ALDH1A1RAB9ABRD4CYP3A4CYP2D6
SCHEMBL3104373 0.80 BRD4 (0.36) IDO1TDO2KCNH2BRD4CYP2A6
SCHEMBL3101188 0.79 IDO1 (0.38) IDO1TDO2RAB9ABRD4CYP3A4
SCHEMBL3101593 0.79 BRD4 (0.37) IDO1TDO2ALDH1A1BRD4MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR IDO1 1206/4885TDO2 1785/4885PDE4A 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.